WWW.FRO.BE


>> Publicatielijst V-Z

THE PURPOSE OF RESEARCH IS TO INCREASE OUR INSIGHT IN FUNCTION AND DYSFUNCTION OF THE VISUAL SYSTEM


List of Papers by Laureates of FRO (Oct 2005) (V t/m Z)


VAN AKEN Elisabeth

1. De Bleecker J.L., Meire V.I., Declercq W. and Van Aken E. (1999). Immunolocalisation of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul. Disord. 9 (4), 239-246

2. Van Hoorde L., Van Aken E. and Mareel M. (2000). Collagen type I: a substrate and a signal for invasion (review). Prog. Mol. Subcell. Biol. 25, 105-134

3. Van Aken E., Papeleu P., De Potter P., De Laey J.J. and Mareel M. (2000). Cadherin expression in the eye (review). Bull. Soc. belge Ophtalmol. 278, 55-59

4. Van Aken E., De Wever O., Correia da Rocha A.S. and Mareel M. (2001). Defective E-cadherin/catenin complexes in human cancer (review). Virchows Arch. 439 (6), 725-751

5. Van Aken E., Papeleu P., De Potter P., Bruyneel E., Philippe J., Seregard S., Kvanta A., De Laey J.J. and Mareel M.M. (2002). Structure and function of the N-cadherin/catenin complex in retinoblastoma. Invest. Ophthalmol. Vis. Sci. 43 (3), 595-602

6. Stalmans P., Van Aken E., Veckeneer M., Feron E.J. and Stalmans I. (2002). Toxic effect of indocyanine green on retinal pigment epithelium related to osmotic effects of the solvent. Am. J. Ophthalmol. 134 (2), 282-285

7. Rodrigues S., Van Aken E., Van Bocxlaer S., Attoub S., Nguyen Q.D., Bruyneel E., Westley B.R., May F.M., Thim L., Mareel M., Gespach C. and Emami S. (2003). Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J. 17 (1), 7-16

8. Van Aken E.H., De Wever O., Van Hoorde L., Bruyneel E., De Laey J.J. and Mareel M.M. (2003). Invasion of retinal pigment epithelial cells: N-cadherin, hepatocyte growth factor and focal adhesion kinase. Invest. Ophthalmol. Vis. Sci. 44 (2), 463-472

9. Stalmans P., Van Aken E.H., Melles G., Veckeneer M., Feron E.J. and Stalmans I. (2003). Trypan blue not toxic for retinal pigment epithelium in vitro. Am. J. Ophthalmol. 135 (2), 234-236


VAN TENTEN Yasmine

1. Tassignon M.J., De Groot V., Vervecken F. and Van Tenten Y. (1998). Secondary closure of posterior continuous curvilinear capsulorhexis in normal eyes and eyes at risk for postoperative inflammation. J. Cataract Refract. Surg. 24 (10), 1333-1338

2. Van Tenten Y., De Wolf A., Willekens B., Vrensen G.F. and Tassignon M.J. (1999). Temperature threshold for cell death of lens epithelial cells in a human capsular bag model. Exp. Eye Res. 69 (5), 569-574

3. Van Tenten Y., De Groot V., Wuyts F.L. and Tassignon M.J. (2000). Quantitative measurement of the PCCC area in the postoperative period. Br. J. Ophthalmol. 84 (10), 1117-1120

4. Van Tenten Y., Schuitmaker H.J., De Groot V., Willekens B., Vrensen G.F. and Tassignon M.J. (2000). Cell biological mechanisms underlying posterior capsule opacification: search for a therapy. Bull. Soc. belge. 278, 61-66

5. Van Tenten Y., Schuitmaker H.J., De Wolf A., Willekens B., Vrensen G.F. and Tassignon M.J. (2001). The effect of photodynamic therapy with bacteriochlorin A on lens epithelial cells in a capsular bag model. Exp. Eye Res. 72 (1), 41-48

6. Van Tenten Y., Schuitmaker H.J., De Groot V., Willekens B., Vrensen G.F. and Tassignon M.J. (2002). A preliminary study on the prevention of posterior capsule opacification by photodynamic therapy with bacteriochlorin A in rabbits. Ophthalmic Res. 34 (3), 113-118

7. De Groot V., Vrensen G.F., Willekens B., Van Tenten Y. and Tassignon M.J. (2003). In vitro study on the closure of posterior capsulorrhexis in the human eye. Invest. Ophthalmol. Vis. Sci. 44 (5), 2076-2083


WEYENBERG Wim

1. Weyenberg W. and Ludwig A. (2002). In vitro assessment of the interaction mechanisms between mucin and a cationic cellulosic derivative by rheological methods using an experimental design. Pharmazie. 57 (9), 628-631

2. Weyenberg W., Vermeire A., Remon J.P. and Ludwig A. (2003). Characterization and in vivo evaluation of ocular bioadhesive minitablets compressed at different forces. J. Control Release. 89 (2), 329-340

3. Hornof M., Weyenberg W., Ludwig A. and Bernkop-Schnurch A. (2003). Mucoadhesive ocular insert based on thiolated poly(acrylic acid): development and in vivo evaluation in humans. J. Control Release. 89 (3), 419-428

4. Weyenberg W., Todorov V. and Ludwig A. (2004). Rheological evaluation of the influence of sterilisation on ocular gels using an experimental design. Pharmazie. 59 (2), 121-125

5. Weyenberg W., Vermeire A., D'Haese E., Vanhaelewyn G., Kestelyn P., Callens F., Nelis H.J., Remon J.P. and Ludwig A. (2004). Effect of different sterilisation methods on the properties of bioadhesive powders and ocular minitablets, and clinical evaluation. Eur. J. Pharm. Sci. 23 (1), 77-87

6. Weyenbergh W., Vermeire A., Dhondt M.M., Adriaens E., Kestelyn P., Remon J.P. and Ludwig A. (2004). Ocular bioerodible minitablets as strategy for the management of microbial keratitis. Invest. Ophthalmol. Vis. Sci. 45 (9), 3229-3233

7. Dillen K., Weyenberg W., Vandervoort J. and Ludwig A. (2004). The influence of the use of viscosifying agents as dispersion media on the drug release properties from PLGA nanoparticles. Eur. J. Pharm. Biopharm. 58 (3), 539-549

8. Weyenberg W., Vermeire A., Vandervoort J., Remon J.P. and Ludwig A. (2005). Effects of roller compaction settings on the preparation of bioadhesive granules and ocular minitablets. Eur. J. Pharm. Biopharm. 59 (3), 527-536

9. Weyenberg W., Vermeire A., Remon J.P. and Ludwig A. (2005). Development and evaluation of sustained release ocular minitablets. J. Control Release. 101 (1-3), 371-374

10. Bozdag S., Weyenberg W. and Ludwig A. (2005). Rheological evaluation of dispersions, prepared with different non- and gamma-irradiated bioadhesive cospray dried powder mixtures. Pharmazie. 60 (8), 593-597


WILLERMAIN François

1. Willermain F., Caspers-Velu L., Baudson N., Dubois C., Hamdane M., Willems F., Velu T. and Bruyns C. (2000). Role and expression of CD40 on human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 41 (11), 3485-3491

2. Willermain F., Caspers-Velu L., Nowak B., Stordeur P., Mosselmans R., Salmon I., Velu T. and Bruyns C. (2002). Retinal pigment epithelial cells phagocytosis of T lymphocytes: possible implication in the immune privilege of the eye. Br. J. Ophthalmol. 86 (12), 1417-1421

3. Willermain F., Greiner K. and Forrester J.V. (2002). Intensive immunosuppression treatment for central retinal vein occlusion in a young adult: a case report. Ocul. Immunol. Inflamm. 10 (2), 141-145

4. Cabay L., Willermain F., Bruyns C., Verdebout J.M., Witta Y., Baffi J., Velu T., Libert J., Caspers-Velu L., Maho A., Lespagnard L. (2003). CXCR4 expression in vitreoretinal membranes. Br. J. Ophthalmol. 87 (5), 567-569

5. Bali E., Willermain F., Caspers-Velu L., Dubois C., Dehou M.F., Velu T., Libert J. and Bruyns C. (2003). IL-10 in vivo gene expression in a cell-induced animal model of proliferative vitreoretinopathy. Int. J. Mol. Med. 12 (3), 305-310

6. Willermain F., Greiner K. and Forrester J.V. (2003). Atypical end-stage birdshot retinochoroidopathy. Ocul. Immunol. Inflamm. 11 (4), 305-307

7. Greiner K., Murphy C.C., Willermain F., Duncan L., Plskova J., Hale G., Isaacs J.D. and Dick A.D. (2004). Anti-TNFalpha therapy modulates the phenotype of peripheral blood CD4+ T cells in patients with posterior segment intraocular inflammation. Invest. Ophthalmol. Vis. Sci. 45 (1), 170-176


You can find this text at FRO
http://www.fro.be

The URL is:
http://www.fro.be/index.php?op=content&id=29